نتایج جستجو برای: predictive biomarker

تعداد نتایج: 196512  

2014
HC Qu S Yan XL Zhang XW Zhu YL Liu P Wang

To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgr...

2014
Ning Li Zizheng Li Ping Wang

To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgr...

Journal: :Clinical lung cancer 2014
Tomas Slavik Fatima Asselah Najla Fakhruddin Ahmed El Khodary Fairouz Torjman Elia Anis Martin Quinn Azzam Khankan Keith M Kerr

The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. However, such predictive molecular testing is not currently a universally used prac...

2015
Richard Emsley Matthias Pierce Graham Dunn

Stratified medicine requires identifying predictive markers to determine differential treatment effects for subgroups. Ideally, these markers are then validated in prospective randomised trials. However, many of the methods for the analysis and validation of markers are based on there being a single marker. For example, a biomarker stratified trial design typically stratifies on a single binary...

2010
Sabine Tejpar Monica Bertagnolli Fred Bosman Heinz-Joseph Lenz Levi Garraway Frederic Waldman Robert Warren Andrea Bild Denise Collins-Brennan Hejin Hahn D. Paul Harkin Richard Kennedy Mohammad Ilyas Hans Morreau Vitali Proutski Charles Swanton Ian Tomlinson Mauro Delorenzi Roberto Fiocca Eric Van Cutsem Arnaud Roth

The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit from a specific treatment. Despite more than two decades of research into the molecular genetics of colon cancer, there is a lack of prognostic and predictive molecular biomark...

2017
Linda Zuurbier Arman Rahman Martijn Cordes Jennifer Scheick Tse J. Wong François Rustenburg Jesu Christopher Joseph Peter Dynoodt Rory Casey Paul Drillenburg Michael Gerhards Ana Barat Rut Klinger Bozena Fender Darran P. O’Connor Johannes Betge Matthias P. Ebert Timo Gaiser Jochen H. M. Prehn Arjan W. Griffioen Nicole C. T. van Grieken Bauke Ylstra Annette T. Byrne Laurens G. van der Flier William M. Gallagher Ruben Postel

Bevacizumab (bvz) is currently employed as an anti-angiogenic therapy across several cancer indications. Bvz response heterogeneity has been well documented, with only 10-15% of colorectal cancer (CRC) patients benefitting in general. For other patients, clinical efficacy is limited and side effects are significant. This reinforces the need for a robust predictive biomarker of response. To iden...

2013
Matthew J. Marton Russell Weiner

The recent U.S. Food and Drug Administration (FDA) coapprovals of several therapeutic compounds and their companion diagnostic devices (FDA News Release, 2011, 2013) to identify patients who would benefit from treatment have led to considerable interest in incorporating predictive biomarkers in clinical studies. Yet, the translation of predictive biomarkers poses unique technical, logistic, and...

2014
Kinga Malottki Mousumi Biswas Jonathan J Deeks Richard D Riley Charles Craddock Philip Johnson Lucinda Billingham

OBJECTIVES Stratified medicine is often heralded as the future of clinical practice. Key part of stratified medicine is the use of predictive biomarkers, which identify patient subgroups most likely to benefit (or least likely to experience harm) from an intervention. We investigated how many and what predictive biomarkers are currently included in European Medicines Agency (EMA) licensing. S...

2011
Marije F Bakker Suzanne MM Verstappen Paco MJ Welsing Johannes WG Jacobs Zalima N Jahangier Maaike J van der Veen Johannes WJ Bijlsma Floris PJG Lafeber

INTRODUCTION The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and CPII can predict the long-term course of disease activity and radiographic progression early in the disease course of rheumatoid arthritis (RA). METHODS In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of treatment. Relations of (chang...

Journal: :Digestion 2015
Christine Koch Joerg Trojan

BACKGROUND Gastrointestinal cancers are among the leading causes of cancer-related deaths worldwide. In different tumor types, personalized systemic treatment strategies based upon biomarker-selection were established over the last years. Although there is a flood of targeted agents in clinical development, only a few targeted agents with a predictive biomarker could be established for the trea...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید